Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFINE
2023-507276-53-00Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label trial of navitoclax in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more (4 arms), sponsored by AbbVie Inc. Primary endpoint: Spleen volume reduction ≥35% at Week 24. Started Apr 2024; status: completed.
02
Drugs
navitoclax
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2023-507276-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507276-53-00.